Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”?
At first glance, the two sound like cousins—both extend exclusivity, both protect revenue, both buy time. But in practice, the…

Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the game.
Eurasia looks familiar on the surface—patents, exclusivity, regulatory approvals, enforcement. But the reality is messier: fragmented…

Pharmaceutical patent strategy is often discussed like a courtroom drama: file early, argue hard, win big.
But the real cost isn’t just legal fees—it’s the opportunity cost of building portfolios that look impressive on paper and fail in practice.
In a…

The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t a metaphor. It’s a margin. It’s a formulary decision. It’s a payer contract. And increasingly, it’s a race against the “drug patent clock” that can flip a prod…

Before You Launch: The Freedom-to-Operate Checklist Pharma Teams Wish They Had Earlier
Launching a drug is a sprint disguised as a marathon. The science is hard, the manufacturing is harder, and the regulatory work is relentless. But there’s one risk t…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…